Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Psirenity
Toronto, Ontario, Canadapsirenity.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Psirenity has been granted approval to conduct Jamaica’s first psilocybin clinical trial for managing depression, using immediate-release and controlled-release psilocybin, characterized as a Phase 2 study, with plans for a subsequent Phase 2 trial in an orphan CNS indication.[1][4]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculeNutraceuticalNon-pharmacological therapy
- Industry
- Biotech
02
Partnerships
Scientific Research Council of Jamaica (SRC) – two-year partnership for cooperative studies and clinical work on psilocybin mushrooms and brain health, including cultivation and R&D support.[2]New Leaf Canada – upstream supply, facility, and research support relationship enabling psilocybin research in Canada and Jamaica.[2][8]
Beyond the preview
Go deeper on Psirenity.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psirenity.